ESC Congress 2026 Abstract
Empagliflozin reduced heart chamber volumes alongside other drugs
Over 36 weeks, empagliflozin reduced the heart’s main pumping chamber’s volume after contraction by 6.0 milliliters per square meter of body surface area versus placebo.Over 36 weeks, empagliflozin reduced the heart’s main pumping chamber’s volume after contraction by 6.0 milliliters per square meter of body surface area versus placebo.
Randomized trial · 105 peopleEmpagliflozin
Who was studied105 people with heart failure with reduced ejection fraction, against placebo
What changedEmpagliflozin reduced left ventricular end-systolic volume index by 6.0 mL/m2 compared with placebo
The catchOnly 36 patients were receiving an ARNI and 63 were receiving an MRA
